AIA
AERI

Angeles Investment Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Angeles Investment Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,282
Closed -$163K – 277
2021
Q3 		$163K Buy
+14,282
New +$209K 0.01% 228

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Angeles Investment Advisors's AERI Position: Q4 2021 in Review

Angeles Investment Advisors sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 14,282 shares — an estimated $163K sold.

Angeles Investment Advisors first reported a position in AERI in Q3 2021 and held it in 1 quarter. The position peaked at $163K in Q3 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

  • Angeles Investment Advisors reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Angeles Investment Advisors sold 14,282 Aerie Pharmaceuticals shares in Q4 2021, an estimated $163K.
  • Angeles Investment Advisors first reported a position in Aerie Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Angeles Investment Advisors's Aerie Pharmaceuticals position peaked at $163K in Q3 2021.
  • 129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on Angeles Investment Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.